because of the potential efficacy of gvg in controlling previously therapeutic-resistant seizures and of the absence of evidence of significant toxicity in humans , carefully monitored clinical trials of gvg in therapy-resistant patients with epilepsy should continue .
C0036572
seizures
C0014544
epilepsy